The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 01, 2019

Filed:

Nov. 09, 2012
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Michelle R. Kuhne, Redwood City, CA (US);

Chin Pan, Redwood City, CA (US);

Josephine M. Cardarelli, Redwood City, CA (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/454 (2006.01); A61K 31/69 (2006.01); A61K 31/136 (2006.01); A61K 31/4184 (2006.01); A61K 31/555 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 31/136 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/555 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/69 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.


Find Patent Forward Citations

Loading…